Companies /Healthcare
Phathom Pharmaceuticals Inc
NASDAQ: PHAT Biotechnology
$6.45
▲ $0.17 (+2.71%) today
Markets open · 10:52am ET

Phathom Pharmaceuticals (PHAT) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
86%
EPS beat rate
+30.93%
Avg. EPS surprise
Consecutive EPS beats
PHAT vs Market · 30-day return after each reportPHATS&P 500
−20%0%+20%+40%+47.3%+6.7%Q1 25+37.1%+2.9%Q2 25+10.7%+0.3%Q3 25−22.4%−8.3%Q4 25−13.8%+5.7%Q1 26+6.0%+3.4%Q2 26
−20%0%+20%+40%Q1 25Q3 25Q1 26
PHAT EPS Trend · estimate vs actualEstimateActual
$-1.20$-0.80$-0.40$0.00$-1.07$-1.07Q1 25$-0.89$-0.79Q2 25$-0.42$-0.41Q3 25$-0.19$-0.08Q4 25$-0.19$-0.18Q1 26$-0.10$0.00Q2 26$0.03$0.04Q3 26
$-1.20$-0.80$-0.40$0.00Q1 25Q3 25Q1 26Q3 26
PHAT Revenue Trend · estimate vs actualEstimateActual
$0$30.0M$60.0M$90.0M$29.0M$28.5MQ1 25$35.6M$39.5MQ2 25$47.0M$49.5MQ3 25$57.4M$57.6MQ4 25$56.8M$58.3MQ1 26$72.7M$74.3MQ2 26$84.8M$84.7MQ3 26
$0$30.0M$60.0M$90.0MQ1 25Q3 25Q1 26Q3 26

How Often Does Phathom Pharmaceuticals Beat Earnings Estimates?

Phathom Pharmaceuticals beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 6 quarters in a row.

PHAT quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Non-GAAP figure excludes $5,921 thousand stock-based compensation, $10,009 thousand non-cash interest on revenue interest financing liability, and $953 thousand debt discount amortization; GAAP net loss per share was $(0.16) $0.04 est. $0.03 +39.86% $84.7M est. $84.8M −0.12%
Q2 2026 $0.00 est. $-0.10 +100.00% $74.3M est. $72.7M +2.18%
Q1 2026 $-0.18 est. $-0.19 +7.36% $58.3M est. $56.8M +2.63%
Q4 2025 $-0.08 est. $-0.19 +57.45% $57.6M est. $57.4M +0.24%
Q3 2025 $-0.41 est. $-0.42 +1.20% $49.5M est. $47.0M +5.34%
Q2 2025 $-0.79 est. $-0.89 +10.99% $39.5M est. $35.6M +11.02%
Q1 2025 $-1.07 est. $-1.07 −0.38% $28.5M est. $29.0M −1.71%

Figures from SEC filings and company reports. Not investment advice.